Hockly E - Search Results

1

The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes.

Woodman B, Butler R, Landles C, Lupton MK, Tse J, Hockly E, Moffitt H, Sathasivam K, Bates GP. Woodman B, et al. Among authors: hockly e. Brain Res Bull. 2007 Apr 30;72(2-3):83-97. doi: 10.1016/j.brainresbull.2006.11.004. Epub 2006 Dec 5. Brain Res Bull. 2007. PMID: 17352931

2

Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?

Bates GP, Hockly E. Bates GP, et al. Among authors: hockly e. Curr Opin Neurol. 2003 Aug;16(4):465-70. doi: 10.1097/01.wco.0000084223.82329.bb. Curr Opin Neurol. 2003. PMID: 12869804 Review.

3

Standardization and statistical approaches to therapeutic trials in the R6/2 mouse.

Hockly E, Woodman B, Mahal A, Lewis CM, Bates G. Hockly E, et al. Brain Res Bull. 2003 Sep 30;61(5):469-79. doi: 10.1016/s0361-9230(03)00185-0. Brain Res Bull. 2003. PMID: 13679245

4

Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease.

Benn CL, Landles C, Li H, Strand AD, Woodman B, Sathasivam K, Li SH, Ghazi-Noori S, Hockly E, Faruque SM, Cha JH, Sharpe PT, Olson JM, Li XJ, Bates GP. Benn CL, et al. Among authors: hockly e. Hum Mol Genet. 2005 Oct 15;14(20):3065-78. doi: 10.1093/hmg/ddi340. Epub 2005 Sep 23. Hum Mol Genet. 2005. PMID: 16183657

5

Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles.

Smith DL, Portier R, Woodman B, Hockly E, Mahal A, Klunk WE, Li XJ, Wanker E, Murray KD, Bates GP. Smith DL, et al. Among authors: hockly e. Neurobiol Dis. 2001 Dec;8(6):1017-26. doi: 10.1006/nbdi.2001.0438. Neurobiol Dis. 2001. PMID: 11741397

6

Environmental enrichment slows disease progression in R6/2 Huntington's disease mice.

Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C, Lewis CM, Hannan AJ, Bates GP. Hockly E, et al. Ann Neurol. 2002 Feb;51(2):235-42. doi: 10.1002/ana.10094. Ann Neurol. 2002. PMID: 11835380

7

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.

Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP. Hockly E, et al. Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2041-6. doi: 10.1073/pnas.0437870100. Epub 2003 Feb 7. Proc Natl Acad Sci U S A. 2003. PMID: 12576549 Free PMC article.

8

Minocycline and doxycycline are not beneficial in a model of Huntington's disease.

Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PA, Bates GP, Hockly E. Smith DL, et al. Among authors: hockly e. Ann Neurol. 2003 Aug;54(2):186-96. doi: 10.1002/ana.10614. Ann Neurol. 2003. PMID: 12891671

9

Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease.

Hockly E, Tse J, Barker AL, Moolman DL, Beunard JL, Revington AP, Holt K, Sunshine S, Moffitt H, Sathasivam K, Woodman B, Wanker EE, Lowden PA, Bates GP. Hockly E, et al. Neurobiol Dis. 2006 Jan;21(1):228-36. doi: 10.1016/j.nbd.2005.07.007. Epub 2005 Aug 18. Neurobiol Dis. 2006. PMID: 16111888

10

Homocysteine, vitamins and sex.

Hockly E, Brown MJ. Hockly E, et al. Eur Heart J. 1999 Sep;20(17):1222-3. doi: 10.1053/euhj.1999.1672. Eur Heart J. 1999. PMID: 10454973 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters